CNTA · Centessa Pharmaceuticals plc
$0.00
—
End-of-day data · updated 2026-07-28
Market cap
$6B
Enterprise value
$6B
Trailing P/E
—
Forward P/E
-22.8
Dividend yield
—
Beta
1.12
Avg volume
2M
Employees
0K
2D change
—
5D change
—
10D change
—
30D change
—
60D change
—
MTD change
—
YTD change
—
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Technical data is temporarily unavailable for CNTA.
Analyst sentiment over time — CNTA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-04-20
Latest call per bank · past 12 months
Wells Fargo
Equal-Weight$42.00
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-04-20 | Wells Fargo | Downgrade | Overweight → Equal-Weight | $35.00 → $42.00 |
| 2026-04-02 | Guggenheim | Downgrade | Buy → Neutral | $0.00 |
| 2026-04-01 | Leerink Partners | Downgrade | Outperform → Market Perform | $36.00 → $40.00 |
| 2026-03-31 | Wolfe Research | Downgrade | Outperform → Peer Perform | $0.00 |
| 2026-03-31 | Needham | Downgrade | Buy → Hold | $0.00 |
| 2026-02-24 | Wolfe Research | Initiates | Outperform | $0.00 → $40.00 |
| 2026-01-29 | Truist Securities | Maintains | Buy | $33.00 → $38.00 |
| 2026-01-08 | Truist Securities | Maintains | Buy | $30.00 → $33.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
CNTA Price Chart
Loading chart for CNTA…
Fundamentals
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.